Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
For privately held biotechs, IPOs are the most common road to the public markets, but they’re not the only way. Reverse merging with a shell company is an alternate path, and... Read more »
Drugs that treat a form of vision loss known as age related macular degeneration aren’t just big business. They’re also a controversial part of the national debate over high drug prices,... Read more »
[Updated, 11:10 a.m. ET, see below] New York biotech has historically lagged behind more established life sciences hubs like Boston and San Francisco, but collaborations between its research institutions... Read more »
Third Rock Ventures is known for making big bets on risky science, and over the past decade a number of those gambles have paid off for its shareholders. That success has... Read more »
The 2016 election is (thankfully) almost here, and as one biotech analyst noted this week, a possible Democratic victory is to blame for a big October sell-off in biotech stocks. Since... Read more »
How did one of the ambitious gene editing startups in biotech come together? What lessons does Harvard University professor and biotech veteran Vicki Sato have about closing the gender gap after... Read more »
The IPO market has been much more discerning about biotechs in 2016 than it was during the 2013-2015 boom. But Wall Street investors embraced Ra Pharmaceuticals Tuesday evening, enabling the Cambridge,... Read more »
Aduro Biotech ran into some trouble earlier this year when one of its cancer immunotherapies failed a clinical trial. Now the Berkeley, CA, company has a safety problem and a clinical... Read more »
For three years, a group of investors and experienced neuroscience executives have been stealthily advancing one of the more ambitious new startups in neurology, called BlackThorn Therapeutics. Today they’re finally shedding... Read more »
Five years is a long time. But in New York biotech it might as well be a century given how fast things are changing.
Back in 2011, Xconomy held an event... Read more »
Five years ago, in November 2011, a company from Princeton, NJ, called Pharmasset shared news that would have an impact on millions of people around the world with hepatitis C. Its... Read more »
Celgene late Sunday provided more details on one of the more important drugs in its pipeline, a pill the Summit, NJ, company is developing for inflammatory bowel disease. Analysts on Wall... Read more »
Regeneron Pharmaceuticals has seen its share of ups and downs over the years developing a drug for chronic pain that could represent an alternative to addictive opioids. And another roadblock just... Read more »
For close to a decade, Tom Daniel and George Golumbeski comprised perhaps one of the best-known dealmaking duos in biopharma, striking a slew of alliances that established Summit, NJ-based Celgene as... Read more »
On Aug. 4, shares of Bristol-Myers Squibb closed at $75.32. Today, shares are worth just over $50. That means in three months, Bristol has lost a third of its value, equivalent... Read more »
After flying high for a few years, Bluebird Bio has dealt with some adversity. Limitations emerged late last year for a gene therapy the company was developing for the blood diseases... Read more »
The European Society for Medical Oncology’s annual conference wraps up in Copenhagen today. We’ve seen updates on heavyweight immunotherapy programs, potential options for patients with advanced breast cancer, and more. Here’s... Read more »
A few weeks ago, Xconomy spoke with analysts and patient advocates who considered it unlikely that insurers would balk at a potential price of $300,000 a year for eteplirsen (Exondys 51),... Read more »
Earlier this year, Intellia Therapeutics became the second drugmaker using the landmark gene editing technology CRISPR-Cas9 to go public, after Editas Medicine. A third, CRISPR Therapeutics, could be on the... Read more »
December 15, 2016
© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.